Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.

By A. Gallamini, C. Stelitano, R. Calvi, M. Bellei, D. Mattei, U. Vitolo, F. Morabito, M. Martelli, E. Brusamolino, E. Iannitto and 8 more. Blood, 2004

624 citations recorded by the source corpus.

To assess the prognosis of peripheral T-cell lymphoma unspecified, we retrospectively analyzed 385 cases fulfilling the criteria defined by the World Health Organization classification. Factors associated with a worse overall survival (OS) in a univariate analysis were age older than 60 years (P=.0002), equal to or more than 2 extranodal sites (P=.0002), lactic dehydrogenase (LDH) value at normal levels or above (P<.0001), performance status (PS) equal to or more than 2 (P< or =.0001), stage III or higher (P=.0001), and bone marrow involvement (P=.0001). Multivariate analysis showed that age (relative risk, 1.732; 95% CI, 1.300-2.309; P<.0001), PS (relative risk, 1.719; 95% CI, 1.269-2.327, P<.0001), LDH level (relative risk, 1.905; 95% CI, 1.415-2.564; P<.0001), and bone marrow involvement (relative risk, 1.454; 95% CI, 1.045-2.023; P=.026) were factors independently predictive for survival. Using these 4 variables we constructed a new prognostic model that singled out 4 groups at different risk: group 1, no adverse factors, with 5-year and 10-year OS of 62.3% and 54.9%, respectively; group 2, one factor, with a 5-year and 10-year OS of 52.9% and 38.8%, respectively; group 3, 2 factors, with 5-year and 10-year OS of 32.9% and 18.0%, respectively; group 4, 3 or 4 factors, with a 5-year and 10-year OS of 18.3 and 12.6%, respectively (P< or =.0001; log-rank, 66.79).

Subfields: Dermatology, Immunology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/27cb327f05e26719f328b7e8c4b1d293d863eaaa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Elaine S. Jaffe
S. Pileri
N. Harris
J. Connors
K. Savage
L. Rimsza
M. Chhanabhai
J. Armitage

Citations in the corpus

The 2008 WHO classification of lymphomas: implications for clinical practice and translational research (2009, neutral): “Most cases lack distinct genetic or biological alterations, and prognostic models have largely relied on clinical features or generic factors, such as proliferation.(64,65) Nevertheless, progress has been made in the understanding of a number of PTCL entities.”
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. (2009, neutral): “Number of cases 92 35 9 Median age, y (range) 52 (21-89) 45 (19-86) .”
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. (2008, methodology): “T-cell prognostic index developed for PTCL-NOS (PIT) ( 19 ) was also applied to”